201 related articles for article (PubMed ID: 26575256)
1. Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate.
Cramer JA; Velez FF; Anastassopoulos KP; Bond TC; Gilliam FG; Ryvlin P; Specchio LM; Wang X; Blum D; Moreira J; Rocha F
Epilepsy Behav; 2015 Dec; 53():149-53. PubMed ID: 26575256
[TBL] [Abstract][Full Text] [Related]
2. Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results.
Cramer JA; Colman S; Anastassopoulos KP; Grinnell T; Mehta D; Williams GR
Epilepsy Behav; 2020 Nov; 112():107312. PubMed ID: 32801102
[TBL] [Abstract][Full Text] [Related]
3. Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-onset seizures: A pooled analysis of phase III clinical trials of eslicarbazepine acetate.
Velez FF; Bond TC; Anastassopoulos KP; Wang X; Sousa R; Blum D; Cramer JA
Epilepsy Behav; 2017 Mar; 68():203-207. PubMed ID: 28236698
[TBL] [Abstract][Full Text] [Related]
4. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial.
Kirkham F; Auvin S; Moreira J; Gama H; Falcão AC; Rocha JF; Soares-da-Silva P
Epilepsy Behav; 2020 Apr; 105():106962. PubMed ID: 32151803
[TBL] [Abstract][Full Text] [Related]
7. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.
Jóźwiak S; Veggiotti P; Moreira J; Gama H; Rocha F; Soares-da-Silva P
Epilepsy Behav; 2018 Apr; 81():1-11. PubMed ID: 29454255
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D;
BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756
[TBL] [Abstract][Full Text] [Related]
9. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America.
Sperling MR; Harvey J; Grinnell T; Cheng H; Blum D;
Epilepsia; 2015 Apr; 56(4):546-55. PubMed ID: 25689448
[TBL] [Abstract][Full Text] [Related]
11. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity testing of the Seizure Severity Questionnaire (SSQ).
Borghs S; de la Loge C; Brabant Y; Cramer J
Epilepsy Behav; 2014 Feb; 31():281-5. PubMed ID: 24275520
[TBL] [Abstract][Full Text] [Related]
13. Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.
Mintzer S; Wechsler RT; Rogin JB; Gidal BE; Schwab M; Ben-Menachem E; Carreño M; da Silva PS; Moreira J; Li Y; Blum D; Grinnell T
Epilepsy Res; 2018 Mar; 141():83-89. PubMed ID: 29499473
[TBL] [Abstract][Full Text] [Related]
14. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
16. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.
Correia FD; Freitas J; Magalhães R; Lopes J; Ramalheira J; Lopes-Lima J; Chaves J
Epilepsy Res; 2014 Oct; 108(8):1399-405. PubMed ID: 25060997
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.
Gil-Nagel A; Lopes-Lima J; Almeida L; Maia J; Soares-da-Silva P;
Acta Neurol Scand; 2009 Nov; 120(5):281-7. PubMed ID: 19832771
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.
Gil-Nagel A; Elger C; Ben-Menachem E; Halász P; Lopes-Lima J; Gabbai AA; Nunes T; Falcão A; Almeida L; da-Silva PS
Epilepsia; 2013 Jan; 54(1):98-107. PubMed ID: 22882018
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.
Lee SK; Lee SA; Hong SB; Cho YW; Castilla-Fernández G; Fonseca MM; Moreira J; Gama H; Holenz J
Clin Transl Sci; 2024 May; 17(5):e13802. PubMed ID: 38787305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
